1. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16(7):1711-1718.
2. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349(9053):675-682.
3. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997;349(9053):667-674.
4. Tisdale JE, Follin SL, Ordelova A, et al. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. Journal of clinical pharmacology. 1995;35(4):351-356.
5. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. Journal of the American College of Cardiology. 1997;30(3):791-798.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457- 2471.
7. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama. 2007;298(10):1189-1195.
8. Martino E, Bartalena L, Bogazzi F, et al. The Effects of Amiodarone on the Thyroid. Endocrine Reviews. 2001;22(2):240-254.
9. Basaria S, Cooper DS. Amiodarone and the thyroid. The American Journal of Medicine. 2005;118(7):706-714.
10. Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgrad Med J. 1986;62(732):909-914.
11. 布施 養. ヨウ素をめぐる医学的諸問題－日本人のヨウ素栄養の特異性. Biomedical Research on Trace Elements. 2013;24(3):117-152.
12. Benassi F, Molardi A, Righi E, et al. ECMO for pulmonary rescue in an adult with amiodarone-induced toxicity. Heart Vessels. 2015;30(3):410-415.
13. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clinical endocrinology. 1987;26(2):227-237.
14. Martino E, Safran M, Aghini-Lombardi F. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Annals of Internal Medicine. 1984;101(1):28-34.
15. Ahmed S, Van Gelder IC, Wiesfeld ACP, et al. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clinical Endocrinology. 2011;75(3):388- 394.
16. Lee KF, Lee KM, Fung TT. Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. Hong Kong medical journal. 2010;16(6):434-439.
17. Schaan BD, Cunha CP, Bruch RS. Amiodarone-induced thyroid dysfunction in a tertiary center in south Brazil. Arquivos Brasileiros de Endocrinologia & Metabologia. 2005;49(6):916-922.
18. Sidhu J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM: An International Journal of Medicine. 2003;96(12):949-950.
19. Stan MN, Ammash NM, Warnes CA, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease - A cohort study. International Journal of Cardiology. 2013;167(3):821-826.
20. Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodinereplete area: epidemiological and clinical data. Endokrynologia Polska. 2012;63(1):2- 9.
21. Aleksić Z, Aleksić A. Incidence of amiodarone-induced thyroid dysfunction and predictive factors for their occurrence. Medicinski pregled. 2011;64(11-12):533- 538.
22. Martino E, Aghini-Lombardi F, Bartalena L, et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Archives of Internal Medicine. 1994;154(23):2722-2726.
23. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. The American journal of medicine. 1991;91(5):507-511.
24. Huang C-J, Chen P-J, Chang J-W, et al. Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. International Journal of Clinical Pharmacy. 2014;36(2):405-411.
25. Uchida T, Kasai T, Takagi A, et al. Prevalence of Amiodarone-Induced Thyrotoxicosis and Associated Risk Factors in Japanese Patients. International Journal of Endocrinology 2014;2014.
26. Sato K, Miyakawa M, Eto M, et al. Clinical Characteristics of AmiodaroneInduced Thyrotoxicosis and Hypothyroidism in Japan. Endocrine Journal. 1999;46(3):443-451.
27. Malli F, Bargiota A, Theodoridou K, et al. Increased primary autoimmune thyroid diseases and thyroid antibodies in sarcoidosis: evidence for an underrecognised extrathoracic involvement in sarcoidosis? Hormones (Athens). 2012;11(4):436-443.
28. Waldhauser KM, Torok M, Ha HR, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther. 2006;319(3):1413-1423.
29. Yamazaki K, Mitsuhashi T, Yamada E, et al. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid : official journal of the American Thyroid Association. 2007;17(12):1189-1200.
30. Kono Y, Nakamura K, Kimura H, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J. 2006;70(8):1001-1005.
31. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2002;105(24):2867-2871.
32. Jabrocka-Hybel A, Bednarczuk T, Bartalena L, et al. Amiodarone and the thyroid. Endokrynologia Polska. 2015;66(2):176-196.
33. 藤田 利. 副作用評価におけるシグナル検出. 薬剤疫学. 2009;14(1):27-36.
34. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel Statistical Tools for Monitoring the Safety of Marketed Drugs. Clinical Pharmacology & Therapeutics. 2007;82(2):157-166.
35. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety. 2009;18(6):427-436.
36. Lawrence Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiology and Drug Safety. 2003;12(7):559-574.
37. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. European journal of clinical pharmacology. 1998;54(4):315-321.
38. van Puijenbroek EPEnP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and drug safety. 2002;11(1):3-10.
39. Abe J, Umetsu R, Mataki K, et al. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. Journal of Pharmaceutical Health Care and Sciences. 2016;2(1):14-14.
40. Nakamura M, Umetsu R, Abe J, et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. Journal of Pharmaceutical Health Care and Sciences. 2015;1(1):34-34.
41. Sauzet O, Carvajal A, Escudero A, et al. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36(10):995-1006.
42. Beddows SA, Page SR, Taylor AH, et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochemical pharmacology. 1989;38(24):4397-4403.
43. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. American heart journal. 1983;106(4 Pt 2):840-847.
44. Yamato M, Wada K, Fujimoto M, et al. Association between Ndesethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction. European Journal of Clinical Pharmacology. 2017;73(3):289-296.
45. Yamato M, Wada K, Hayashi T, et al. Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction. Clinical Drug Investigation. 2018;38(1):39-48.
46. Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology. 2014;171(3):363-368.
47. Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation. 1999;100(2):149-154.
48. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Annals of internal medicine. 1997;126(1):63-73.
49. Bolt MW, Card JW, Racz WJ, et al. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ther. 2001;298(3):1280-1289.
50. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134(5):2277-2282.
51. Araujo AAd, Pereira AdSBF, Medeiros CACXd, et al. Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitis. PloS one. 2017;12(8):e0183506-e0183506.
52. Esteghamati A, Eskandari D, Mirmiranpour H, et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Clinical Nutrition. 2013;32(2):179-185.
53. Kukidome D, Nishikawa T, Sonoda K, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes. 2006;55(1):120-127.
54. Sato N, Takasaka N, Yoshida M, et al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respiratory research. 2016;17(1):107.
55. Zhao S, Nishimura T, Chen Y, et al. Systems pharmacology of adverse event mitigation by drug combinations. Science Translational Medicine. 2013;5(206):206ra140-206ra140.
56. Nagashima T, Shirakawa H, Nakagawa T, et al. Prevention of antipsychoticinduced hyperglycaemia by Vitamin D: A data mining prediction followed by experimental exploration of the molecular mechanism. Scientific Reports. 2016;6(April):1-10.
57. Asghar O, Alam U, Hayat SA, et al. Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Current cardiology reviews. 2012;8(4):253-264.
58. Pennathur S, Heinecke JW. Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal. 2007;9(7):955-969.
59. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 2013;50(4):569-577.
60. Umetsu R, Abe J, Ueda N, et al. Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data. Biological and Pharmaceutical Bulletin. 2015;38(11):1689-1699.
61. El-serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460-468.
62. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011;2011:439463.
63. Choi SM, Jang A-H, Kim H, et al. Metformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice. Journal of Korean Medical Science. 2016;31(9):1419- 1425.
64. Li L, Huang W, Li K, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget. 2015;6(41):43605-43619.
65. Rangarajan S, Bone NB, Zmijewska AA, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nature medicine. 2018;24(8):1121-1131.
66. Wang J, Wang Y, Han J, et al. Metformin attenuates radiation-induced pulmonary fibrosis in a murine model. Radiation Research. 2017;188(1):105-113.
67. Martin WJ, Rosenow EC. Amiodarone Pulmonary Toxicity: Recognition and pathogenesis (Part 2). Chest. 1988;93(6):1242-1248.
68. Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ (Clinical research ed). 1997;314(7081):619-620.
69. Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population -based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.
70. Jain SK. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. Journal of Biological Chemistry. 1989;264(35):21340-21345.
71. Jain SK, Levine SN, Duett J, et al. Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. Metabolism: clinical and experimental. 1990;39(9):971-975.
72. Alam MA, Chowdhury MRH, Jain P, et al. DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol Metab Syndr. 2015;7:107.
73. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760.
74. Hwang HJ, Chung HS, Jung TW, et al. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms. Mol Cell Endocrinol. 2015;405:25-34.
75. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076- 2082.
論文の公開元へ
